The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the usefulness of a drug, denosumab, to prevent the
loss of bone in participants legs due to SCI. This drug is FDA approved to treat osteoporosis
in women after menopause who have an increased risk for fractures, to treat women receiving
certain treatments for breast cancer who have an increased risk of fractures, and to treat
bone loss in men receiving certain treatments for prostate cancer who have increased risk for
fractures. This drug is considered experimental for the purpose of this study. Study
participation will last for approximately 12 months (6 study visits total), visits will range
from1-4.5 hours depending on the number of tests that need to be completed. The study is a
double-blinded placebo trail in which the participant will be randomly assigned to on of two
groups, Denosumab injections or placebo - inactive salt solution injections.